Cargando…

An Update on the Treatment of Papillary Renal Cell Carcinoma

SIMPLE SUMMARY: Papillary renal cell carcinoma is the second most common type of kidney cancer, after clear cell kidney cancer. Given that it is relatively rare, studying this disease has been quite a challenge. New treatments and techniques for studying papillary kidney cancer have led to some mean...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chawla, Neal S., Sayegh, Nicolas, Prajapati, Sweta, Chan, Elyse, Pal, Sumanta K., Chehrazi-Raffle, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913225/ https://www.ncbi.nlm.nih.gov/pubmed/36765524 http://dx.doi.org/10.3390/cancers15030565

Ejemplares similares

Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles
por: Govindarajan, Ameish, et al.
Publicado: (2023)

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
por: Barata, Pedro C, et al.
Publicado: (2023)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
por: Meza, Luis, et al.
Publicado: (2023)

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC)
por: Ebrahimi, Hedyeh, et al.
Publicado: (2023)

Renal cell carcinoma: An update for the practicing urologist
por: Pal, Sumanta K., et al.
Publicado: (2015)

Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2023)

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
por: Dizman, Nazli, et al.
Publicado: (2022)

Characterizing the outcomes of metastatic papillary renal cell carcinoma
por: Connor Wells, John, et al.
Publicado: (2017)

Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California
por: Salgia, Nicholas J., et al.
Publicado: (2021)

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
por: Gong, Jun, et al.
Publicado: (2018)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma
por: Meza, Luis, et al.
Publicado: (2022)

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
por: Dudani, Shaan, et al.
Publicado: (2021)

How to Treat Renal Cell Carcinoma: The Current Treatment Landscape and Cardiovascular Toxicities
por: Castro, Daniela V., et al.
Publicado: (2022)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
por: Salgia, Meghan, et al.
Publicado: (2017)

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
por: Vogelzang, Nicholas J., et al.
Publicado: (2017)

Cytoreductive Nephrectomy in 2021: Obsolete
por: Meza, Luis, et al.
Publicado: (2021)

Metastasis in renal cell carcinoma: Biology and implications for therapy
por: Gong, Jun, et al.
Publicado: (2016)

The Gut Microbiome and Metastatic Renal Cell Carcinoma
por: Meza, Luis, et al.
Publicado: (2023)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
por: Gong, Jun, et al.
Publicado: (2019)

Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era
por: Pal, Sumanta K., et al.
Publicado: (2013)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2018)

Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
por: Meza, Luis, et al.
Publicado: (2023)

Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report
por: Ferlicot, Sophie, et al.
Publicado: (2021)

Case of hereditary papillary renal cell carcinoma
por: Mustafa, Sadaf, et al.
Publicado: (2012)

Prognostic models in papillary renal cell carcinoma
por: Attalla, Kyrollis, et al.
Publicado: (2020)

Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies
por: Guha, Avirup, et al.
Publicado: (2022)

Update on the treatment of metastatic renal cell carcinoma
por: Medina López, Rafael Antonio, et al.
Publicado: (2022)

Unique Spectrum of Activating BRAF Alterations in Prostate Cancer
por: Chehrazi-Raffle, Alex, et al.
Publicado: (2023)

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data
por: Vogelzang, Nicholas J., et al.
Publicado: (2018)

The Morphological Spectrum of Papillary Renal Cell Carcinoma and Prevalence of Provisional/Emerging Renal Tumor Entities with Papillary Growth
por: Lobo, João, et al.
Publicado: (2021)

OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
por: Beckermann, Kathryn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m6lmpfc7v8vgm0b8k6nij4eueo